

**Global Bridges at Mayo Clinic and Pfizer Global Medical Grants  
Quality Improvement Request For Proposals (RFP)  
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis  
(Asia, Latin America, Africa and Middle East)  
*Applications invited in English, Spanish, French, Mandarin and Arabic***

**Background and Purpose of this RFP**

Amyloidosis is often misdiagnosed. For example, it is estimated that the correct diagnosis of TTR amyloidosis is delayed by years, in part because it is a **multisystemic** disorder. Our goal is to help accelerate this patient journey by supporting capacity building programs.

Last year, Global Bridges at Mayo Clinic and Pfizer Global Medical Grants launched an RFP focused on raising awareness and closing knowledge gaps to reduce the time it takes for patients to be correctly diagnosed and make treatment more accessible, while supporting the development of a global network of TTR amyloidosis experts. Expanding the community of practice will help decrease the distance patients need to travel to be diagnosed, although valuable guidance may still be obtained from experienced centers further from home.

This RFP is a continuation of this project focused on supporting Quality Improvement initiatives, addressing this need in countries located within Asia, Latin America, Africa, and the Middle East.

It is **not our intent to support research** projects. Any research projects will be considered out of scope for this project. Examples of **out of scope** projects include clinical research projects, basic science research, prevalence studies, registry development, health services research and outcomes research.

**Geographic Scope**

Asia, Latin America, Africa, and the Middle East

**Application process**

**Intent to Apply**

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows Global Bridges staff to estimate the potential review workload and plan the review.

By **July 15th**, prospective applicants are asked to send an email to Katie Kemper at [kemper.katherine@mayo.edu](mailto:kemper.katherine@mayo.edu) with the following information:

- Descriptive title of proposed activity
- Name(s) of Project Lead
- Country of activity
- Submitting institution
- Language of Submission (English, French, Spanish, Mandarin OR Arabic)

**A pre-application webinar to answer questions will be held via WebEx on Friday, June 25, 2021 at 9am EDT. Register using this [link](#).**

	<p><b>By August 16<sup>th</sup></b>, applicants must submit their Full Proposal as described in the “<b>How to Submit</b>” section below.</p>
<b>Funding and Administration of Projects</b>	<p>Project proposals will be reviewed and recommended by an independent expert advisory panel. Projects selected for funding will be funded directly by Pfizer Inc.</p> <p>Operational and technical support for funded projects will be provided by Mayo Clinic.</p>
<b>Applicant Eligibility</b>	<p>Applications are invited from institutions, organizations or associations, e.g. professional schools, hospitals, healthcare systems, universities, patient advocacy groups, professional associations, government agencies</p> <p>Grants can only be awarded to organizations, not individuals or medical practice groups.</p>
<b>Clinical Area</b>	<p>TTR Amyloidosis (any organ system)</p>
<b>Characteristics of a Successful Proposal</b>	<p>In order to increase the capacity of the health care system to provide more timely diagnosis and appropriate treatment to TTR amyloidosis sufferers <b>in any organ</b>, we are interested in receiving proposals that:</p> <ul style="list-style-type: none"> <li>• Reduce the time to correct diagnosis, among a broad audience of health care professionals, including increasing coordination across specialties; AND</li> <li>• Build on evidence and international best practice; AND</li> <li>• Include a robust and well-defined plan for evaluation and dissemination; AND</li> <li>• Support the development of a global network of health care professionals capable of diagnosing and treating TTR amyloidosis, AND</li> <li>• Support the development of a global network of TTR amyloidosis experts</li> <li>• Include a plan to sustain the project beyond the period of funding.</li> </ul>
<b>Out of Scope of this Call</b>	<p><b>It is not our intent to support research projects.</b> Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Additional examples of <b>out of scope</b> projects include clinical research projects, basic science research, prevalence studies, registry development, health services research and outcomes research.</p>
<b>Funding Available/Maximum Award Levels</b>	<p>Total funding available for this RFP is US \$450,000. We anticipate funding between 2-3 projects.</p>
<b>How to Submit</b>	<p>Applications will be accepted in English, French, Spanish, Mandarin and Arabic. They will then be translated for review by the Expert Review Panel. <b>Please note, however, that the Pfizer website, including navigational prompts, is only in English.</b></p>

	<ol style="list-style-type: none"> <li>1. Please go to <a href="http://www.cybergrants.com/pfizer/QI">http://www.cybergrants.com/pfizer/QI</a> and sign in. First-time users should click “Create your password”.</li> <li>2. Select the following Primary Area of Interest: TTR Amyloidosis</li> <li>3. Select the following Competitive Grant Program Name: <b>2021 RD G - Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis</b></li> <li>4. Complete all required sections of the online application. See Appendix A for details.</li> </ol>
<b>Timing</b>	<p>Proposals must be completed in the CyberGrants system no later than <b>Monday, 16 August 2021</b>.</p> <p>All applicants will be notified of the outcome of their application by email in September. Applicants may also be contacted to provide further clarification in order to support the review of this application.</p> <p>If your grant is approved, the agreement is expected to be signed by both parties within 2021 and without change. Please click <a href="#">here</a> to view the core terms of the agreement. The agreement will be with Pfizer Inc. (based in the United States).</p> <p>Anticipated project start date for funded projects is early 2022.</p>
<b>Questions</b>	<p>If you have any questions regarding this RFP, or to discuss whether your project would be in scope, please contact Katie Kemper at Global Bridges (<a href="mailto:kemper.katherine@mayo.edu">kemper.katherine@mayo.edu</a>) or the Pfizer Grant Officer, Amanda Stein (<a href="mailto:amanda.j.stein@pfizer.com">amanda.j.stein@pfizer.com</a>).</p>

**\*\* OVERVIEW OF QUALITY IMPROVEMENT PROPOSAL REQUIREMENTS ON FOLLOWING PAGES\*\***

## Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis Quality Improvement Proposal Requirements

Applications will be accepted via the online portal ([www.cybergrants.com/pfizer/QI](http://www.cybergrants.com/pfizer/QI)). All sections of your application will need to follow the character limits specified in the online application.\*:

<b>Goals and Objectives</b>	Briefly state the overall goal and objectives of the proposed project
<b>Assessment of Need for the Project</b>	<p>Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.</p> <p>Describe the source and method used to collect the data. Describe how the data were analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.</p>
<b>Target Audience</b>	Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
<b>Project Design and Methods</b>	Outline the proposed methodology and key stages or milestones of your planned approach. <b>Maximum project length is two years.</b>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>• Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.</li> <li>• Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.</li> </ul>
<b>Evaluation and Outcomes</b>	<p>Describe how you will measure the success of your project. What measures and metrics will you use to evaluate the impact of the project? Describe your plan to capture baseline and end-of-project metrics and results. <u>Example</u> metrics include:</p> <ul style="list-style-type: none"> <li>• Number of health care professionals trained</li> <li>• Number of patients diagnosed with TTR Amyloidosis</li> <li>• Number of patients receiving intervention</li> </ul>

<b>Anticipated Project Timeline</b>	Provide an anticipated timeline for your project including project start/end dates
<b>Additional Information</b>	Educational Sustainability: How will the results of the project be shared? How will the project support ongoing improvement in amyloidosis treatment and training?
<b>Organizational Detail</b>	Describe the mission, capability, and relevant previous activity of the applicant organization and how it will facilitate the project. Also include information about collaborating or project-partner organizations as applicable.
<b>Monetary Request</b>	<p>Please indicate total monetary amount being requested for this project in United States Dollars (USD).</p> <p>While estimating your budget please keep the following items in mind:</p> <ul style="list-style-type: none"> <li>○ Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: Pfizer does not provide funding for capital equipment.</li> <li>○ Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please <a href="#">click here</a> for details.</li> <li>○ It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription).</li> </ul>

\*The online application also includes the fields noted above. The text in those fields should be the same text that is included in your Full Proposal document.